Gilteritinib, a targeted agent developed by Astellas, Japan, for the treatment of FLT3-mutated AML, shows a significant inhibitory activity against FLT3-ITD and FLT3-TKD mutations (8–10). The gene discussed is FLT3; the disease is acute myeloid leukemia.